Milestone Pharmaceuticals Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| MIST | HRTX | RNA | RVX.TO | CNTB | ZVRA | |
|---|---|---|---|---|---|---|
| Market cap | 96.17M | 56.69M | 148.48M | 27.54M | 49.15M | 663.32M |
| P/E (TTM) | — | — | — | — | — | 9.2 |
| Forward P/E | -1.0 | -2.7 | -1.5 | — | -1.0 | 10.4 |
| Price/book | 6.0 | 9.6 | 0.7 | -0.2 | 1.8 | 4.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −57.83% | −74.77% | −40.88% | −20.00% | −54.07% | +1.89% |
| Today | +1.74% | +4.88% | −0.46% | +6.67% | +0.83% | +8.87% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All MIST news ›Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial
Milestone is pursuing a single-study registration pathway to add AFib-RVR treatment to etripamil’s existing PSVT indication. Milestone Pharmaceuticals (MIST) enrolled its first European participant in ReVeRA-301, the Phase 3 trial…
Financial Survey: vTv Therapeutics (NASDAQ:VTVT) vs. Milestone Pharmaceuticals (NASDAQ:MIST)
Posted by Defense World Staff on Oct 8th, 2026 Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) and vTv Therapeutics (NASDAQ:VTVT – Get Free Report) are both small-cap healthcare companies, but which is the better business? We…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- defenseworld.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 1 articles, not a forecast.